Business ❯ Pharmaceutical Industry ❯ Drug Approval

FDA Approval

Novo Nordisk Lunsumio VELO

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

The one‑minute injection shifts care toward simpler outpatient visits under an approval requiring confirmatory trials.